Cargando…
JAK-STAT Domain Enhanced MUC1-CAR-T Cells Induced Esophageal Cancer Elimination
PURPOSE: Chimeric antigen receptor (CAR)-T cells have shown to play a vital role in anti-tumor functions in hematological malignancies, but have poor efficacy in solid tumors. To improve the activation and proliferation of CAR-T cell in solid tumors, we constructed an enhanced CAR-T cells to increas...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7549884/ https://www.ncbi.nlm.nih.gov/pubmed/33116840 http://dx.doi.org/10.2147/CMAR.S264358 |
_version_ | 1783592868837851136 |
---|---|
author | Zhang, Heng Zhao, Hui He, Xiaolei Xi, Feng Liu, Jiwen |
author_facet | Zhang, Heng Zhao, Hui He, Xiaolei Xi, Feng Liu, Jiwen |
author_sort | Zhang, Heng |
collection | PubMed |
description | PURPOSE: Chimeric antigen receptor (CAR)-T cells have shown to play a vital role in anti-tumor functions in hematological malignancies, but have poor efficacy in solid tumors. To improve the activation and proliferation of CAR-T cell in solid tumors, we constructed an enhanced CAR-T cells to increase the survival of esophageal cancer. MATERIALS AND METHODS: To construct enhanced CAR-T cells, we chose MUC1 as the target of CAR-T cells. Long-term co-culture of target cells and effector cells was applied to verify the antitumor activity of these enhanced MUC1-CAR-T cells in vitro. Moreover, a mouse xenograft model was established to investigate the effects of enhanced MUC1-CAR-T cells on tumor elimination in vivo. RESULTS: In vitro studies showed that enhanced MUC1-CAR-T cells have long-lasting tumor killing and proliferative capabilities. Moreover, animal experiments verified that enhanced MUC1-CAR-T cells had significant antitumor function and a prolonged half-life by subcutaneous transplantation models of esophageal cancer and PDX models of esophageal cancer, in vivo. CONCLUSION: These results indicated that enhanced MUC1-CAR-T cells have a significant cytotoxic effect on esophageal cancer, and may likely to provide a novel strategy for the treatment of esophageal cancer. |
format | Online Article Text |
id | pubmed-7549884 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-75498842020-10-27 JAK-STAT Domain Enhanced MUC1-CAR-T Cells Induced Esophageal Cancer Elimination Zhang, Heng Zhao, Hui He, Xiaolei Xi, Feng Liu, Jiwen Cancer Manag Res Original Research PURPOSE: Chimeric antigen receptor (CAR)-T cells have shown to play a vital role in anti-tumor functions in hematological malignancies, but have poor efficacy in solid tumors. To improve the activation and proliferation of CAR-T cell in solid tumors, we constructed an enhanced CAR-T cells to increase the survival of esophageal cancer. MATERIALS AND METHODS: To construct enhanced CAR-T cells, we chose MUC1 as the target of CAR-T cells. Long-term co-culture of target cells and effector cells was applied to verify the antitumor activity of these enhanced MUC1-CAR-T cells in vitro. Moreover, a mouse xenograft model was established to investigate the effects of enhanced MUC1-CAR-T cells on tumor elimination in vivo. RESULTS: In vitro studies showed that enhanced MUC1-CAR-T cells have long-lasting tumor killing and proliferative capabilities. Moreover, animal experiments verified that enhanced MUC1-CAR-T cells had significant antitumor function and a prolonged half-life by subcutaneous transplantation models of esophageal cancer and PDX models of esophageal cancer, in vivo. CONCLUSION: These results indicated that enhanced MUC1-CAR-T cells have a significant cytotoxic effect on esophageal cancer, and may likely to provide a novel strategy for the treatment of esophageal cancer. Dove 2020-10-08 /pmc/articles/PMC7549884/ /pubmed/33116840 http://dx.doi.org/10.2147/CMAR.S264358 Text en © 2020 Zhang et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Zhang, Heng Zhao, Hui He, Xiaolei Xi, Feng Liu, Jiwen JAK-STAT Domain Enhanced MUC1-CAR-T Cells Induced Esophageal Cancer Elimination |
title | JAK-STAT Domain Enhanced MUC1-CAR-T Cells Induced Esophageal Cancer Elimination |
title_full | JAK-STAT Domain Enhanced MUC1-CAR-T Cells Induced Esophageal Cancer Elimination |
title_fullStr | JAK-STAT Domain Enhanced MUC1-CAR-T Cells Induced Esophageal Cancer Elimination |
title_full_unstemmed | JAK-STAT Domain Enhanced MUC1-CAR-T Cells Induced Esophageal Cancer Elimination |
title_short | JAK-STAT Domain Enhanced MUC1-CAR-T Cells Induced Esophageal Cancer Elimination |
title_sort | jak-stat domain enhanced muc1-car-t cells induced esophageal cancer elimination |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7549884/ https://www.ncbi.nlm.nih.gov/pubmed/33116840 http://dx.doi.org/10.2147/CMAR.S264358 |
work_keys_str_mv | AT zhangheng jakstatdomainenhancedmuc1cartcellsinducedesophagealcancerelimination AT zhaohui jakstatdomainenhancedmuc1cartcellsinducedesophagealcancerelimination AT hexiaolei jakstatdomainenhancedmuc1cartcellsinducedesophagealcancerelimination AT xifeng jakstatdomainenhancedmuc1cartcellsinducedesophagealcancerelimination AT liujiwen jakstatdomainenhancedmuc1cartcellsinducedesophagealcancerelimination |